北京福元医药股份有限公司关于获得化学原料药上市申请批准通知书的公告

Core Points - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Clobetasol [1][3] - The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [2] Summary by Sections Drug Basic Information - The company has obtained the "Chemical Raw Material Drug Listing Application Approval Notice" from the National Medical Products Administration for Clobetasol [1] Other Drug Information - The technical review application for Clobetasol was accepted by the National Medical Products Administration in July 2024, and the approval notice has now been issued [1] Impact on the Company - The approval of Clobetasol will enrich the company's product line and promote sustainable, stable, and healthy development [3] - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a degree of uncertainty [3]